No Data
Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease
The Analyst Landscape: 11 Takes On Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Analyst Ratings
Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6
Lexicon To Present Preclinical IN VIVO Efficacy Data Demonstrating Ability Of New Investigational Compound To Enhance And Maintain Semaglutide-Promoted Weight Loss, At Obesity Week 2024
No Data
No Data